References
- Stiegel R., Desantis C., Jemal A.: Colorectal cancer statistics, 2014. CA. Cancer J. Clin., 2014; 64: 104-117.
- Hanahan D., Weinberg R.A.: Hallmarks of cancer: The next generation. Cell, 2011; 144: 646–674.
- Vaupel P., Thews O., Hoeckel M.: Treatment resistance of solid tumors: role of hypoxia and anemia. Med. Oncol., 2001; 18: 243–259.
- Chen C., Pore N., Behrooz A., Ismail-Beigi F., Maity A.: Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J. Biol. Chem., 2001; 276: 9519-9525.
- Kim J.W., Tchernyshyov I., Semenza G.L., Dang C.V.: HIF-1-me-diated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell Metab., 2006; 3: 177–185.
- Semenza G.L., Jiang B.H., Leung S.W., Passantino R., Concordet J.P., Maire P., Giallongo A.: Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J. Biol. Chem., 1996; 271: 32529–32537.
- Ullah M.S., Davies A.J., Halestrap A.P.: The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1α-dependent mechanism. J. Biol. Chem., 2006; 281: 9030–9037.
- Dang C.V., Le A., Gao P.: MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin. Cancer Res., 2009; 15: 6479–6483.
- Osthus R.C., Shim H., Kim S., Li Q., Reddy R., Mukherjee M., Xu Y., Wonsey D., Lee L.A., Dang C.V.: Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J. Biol. Chem., 2000; 275: 21797–21800.
- Wise D.R., DeBerardinis R.J., Mancuso A., Sayed N., Zhang X.Y., Pfeiffer H.K., Nissim I., Daikhin E., Yudkoff M., et al.: Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc. Natl. Acad. Sci. USA, 2008; 1059: 18782–18787.
- Fantin V.R., St‐Pierre J., Leder P.: Attenuation of LDH‐A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell, 2006; 9: 425–434.
- Gatenby R.A., Gillies R.J.: Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer, 2004; 4: 891–899.
- Burgman P., O’Donoghue J.A., Humm J.L., Ling C.C.: Hypoxia-induced increase in FDG uptake in MCF–7 cells. J. Nucl. Med., 2001; 42: 170–175.
- Busk M., Horsman M.R., Kristjansen P.E., van der Kogel A.J., Bussink J., Overgaard J.: Aerobic glycolysis in cancers: Implications for the usability of oxygen-responsive genes and fluorodeoxyglucose-PET as markers of tissue hypoxia. Int. J. Cancer, 2008; 122: 2726–2734.
- Clavo A.C., Brown R.S., Wahl R.L.: Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J. Nucl. Med., 1995; 36: 1625–1632.
- Gambhir S.S.: Molecular imaging of cancer with positron emission tomography. Nat. Rev. Cancer, 2002; 2: 683–693.
- Mekuria A.N., Abdi A.D.: Drivers of glucose and glutamine metabolism reprogramming in tumor cells and their potential as target for cancer. J. Tumor Res., 2018; 4: 139.
- Phan L.M., Yeung S.C., Lee M.H.: Cancer metabolic reprogramming: Importance, main features, and potentials for precise targeted anti-cancer therapies. Cancer Biol. Med., 2014; 11: 1–19.
- Anastasiou D., Cantley L.C.: Breathless cancer cells get fat on glutamine. Cell Res., 2012; 22: 443–446.
- Metallo C.M., Gameiro P.A., Bell E.L., Mattaini K.R., Yang J., Hiller K., Jewell C.M., Johnson Z.R., Irvine D.J., Guarente L., et al.: Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature, 2011; 481: 380–384.
- Mullen A.R., Wheaton W.W., Jin E.S., Chen P.H., Sullivan L.B., Cheng T., Yang Y., Linehan W.M., Chandel N.S., DeBerardinis R.J.: Reductive carboxylation supports growth in tumor cells with defective mitochondria. Nature, 2011; 481: 385–388.
- Graboń W., Otto-Ślusarczyk D., Baranczyk-Kuźma A.: Influence of oxygen on the Warburg effect: Do cancer cells produce lactate only from glucose? Postępy Hig. Med. Dośw., 2018; 72: 481–490.
- Son J., Lyssiotis C.A., Ying H., Wang X., Ligorio M., Ligorio M., Perera R.M., Ferrone C.R., Mullarky E., Shyh-Chang N., et al.: Glutamine supports pancreatic cancer growth through a KRAS-regulated matabolic pathway. Nature, 2013; 496: 101–105.
- Nicco C., Laurent A., Chreau C., Weill B., Batteux F.: Differential modulation of normal and tumor cell proliferation by reactive oxygen species. Biomed. Pharmacother., 2005; 59: 169–174.
- Overgaad J.: Hypoxic radiosensitization: Adored and ignored. J. Clin. Oncol., 2007; 25: 4066–4074.
- Gasińska A., Biesaga B.: Dwa oblicza hipoksji nowotworów. Nowotwory J. Oncol., 2010; 60: 332.
- Kunz M., Ibrahim S.M.: Molecular responses to hypoxia in tumor cells. Mol. Cancer, 2003; 2: 23.
- Macheda M.W., Rogers S., Best J.D.: Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J. Cell Physiol., 2005; 202: 654–662.
- Medina R.A., Owen G.I.: Glucose transporters: Expression, regulation and cancer. Biol. Res., 2002; 35: 9–26.
- Chung F.Y., Hyang M.Y., Yeh C.S, Chang H.J., Cheng T.L., Yen L.C., Wang J.Y., Lin S.R.: GLUT1 gene is a potential hypoxic marker in colorectal cancer patients. BMC Cancer., 2009; 9: 241.
- Evans S.M., Koch C.J.: Prognostic significance of tumor oxygenation in humans. Cancer Lett. 2003; 195: 1–16.
- Li F., Wang Y., Zeller K.I., Potter J.J., Wonsey D.R., O’Donnell K.A., Kim J.W., Yustein J.T., Lee L.A., Dang C.V.: Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. Mol. Cell. Biol., 2005; 25: 6225–6234.
- Morrish F., Hockenberry D.: MYC and mitochondrial biogenesis. Cold Spring Harb Perspect. Med., 2014; 4: a014225.
- DeBerardinis R.J., Mancuso A., Daikhin E., Nissim I., Yudkoff M., Wehrli S., Thompson C.B.: Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc. Natl. Acad. Sci. USA, 2007;104: 19345–19350.
- Matsuno T., Goto I.: Glutaminase and glutamine synthetase activities in human cirrhotic liver and hepatocellular carcinoma. Cancer Res., 1992; 52: 1192–1194.
- Pérez-Gómez C., Campos-Sandoval J.A., Alonso F.J., Segura J.A., Manzanares E., Ruiz-Sánchez P., González M.E., Márquez J., Matés J.M.: Co-expression of glutaminase K and L isoenzymes in human tumour cells. Biochem. J., 2005; 386: 535–542.
- Qie S., Chu C., Li W., Wang C., Sang N.: ErbB2 activation upregulated glutaminase 1 expression which promotes breast cancer cell proliferation. J. Cell. Biochem., 2014; 115: 498–509.
- Su L., Li J., Yang J., Shi J., Yu D., Ding Y.: Expression of glutaminase 1 gene in breast cancer and its clinical significance in neoadjuvant chemotherapy. Int. J. Clin. Exp. Pathol., 2016; 9: 9311–9317.
- Otto-Ślusarczyk D., Graboń W., Barańczyk-Kuźma A.: Pattern of glutaminase expression in primary colorectal cancer. J. Med. Brasovea, 2010; 2010: 40–43.
- Huang F., Zhang Q., Ma H., Lv Q., Zhang T.: Expression of glutaminase is upregulated in colorectal cancer and of clinical significance. Int. J. Clin. Exp. Pathol., 2014; 7: 1093–1100.
- Xiang L., Mou J., Shao B., Wei Y., Liang H., Takano N., Semenza G.L., Xie G.: Glutaminase 1 expression in colorectal cancer cells is induced by hypoxia and required for tumor growth, invasion, and metastatic colonization. Cell Death Dis., 2019; 10: 40.
- Gao P., Tchernyshyov I., Chang T.C., Lee Y.S., Kita K., Ochi T., Zeller K.I., De Marzo A.M., Van Eyk J.E., Mendell J.T., Dang C.V.: c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature, 2009; 458: 762–765.
- Corn P.G., Ricci M.S., Scata K.A., Arsham A.M., Simon M.C., Dicker D.T., EL-Deiry W.S.: Mxi1 is induced by hypoxia in a HIF-1-dependent manner and protects cells from c-Myc induced apoptosis. Cancer Biol. Ther., 2005; 4: 1285–1294.
- Dang C.V., Kim J.W., Gao P., Yustein J.: The interplay between MYC and HIF in cancer. Nat. Rev. Cancer, 2008; 8: 51–56.
- Zhang H., Gao P., Fukuda R., Kumar G., Krishnamachary B., Zeller K.I., Dang C.V., Semenza G.L.: HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell, 2007; 11: 407–420.
- Altman B.J., Stine Z.E., Dang C.V.: From Krebs to clinic: Glutamine metabolism to cancer therapy. Nat. Rev. Cancer, 2016; 16: 619–634.
- Kovacević Z., Brkljac O., Bajin K.: Control and function of the transamination pathways of glutamine oxidation in tumour cells. Biochem J., 1991; 273: 271–275.
- Graboń W., Otto-Ślusarczyk D., Chrzanowska A., Mielczarek-Puta M., Joniec-Maciejak I., Słabik K., Barańczyk-Kuźma A.: Lactate formation in primary and metastatic colon cancer cell at hypoxia and normoxia. Cell Biochem. Funct., 2016; 34: 483–490.
- Possemato R., Marks K.M., Shaul Y.D., Pacold M.E., Kim D., Birsoy K., Sethumadhavan S., Woo H.K., Jang H.G., Jha A.K., et al.: Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature, 2011; 476: 346–350.
- Li C., Zhang G., Zhao L., Ma Z., Chen H.: Metabolic reprogramming in cancer cells: Glycolysis, glutaminolysis, and Bcl-2 proteins as novel therapeutic targets for cancer. World J. Surg. Oncol., 2016; 14: 15.
- Sun R.C., Denko N.C.: Hypoxic regulation of glutamine metabolism through HIF1 and SIAH2 supports lipid synthesis that is necessary for tumor growth. Cell Metab., 2014; 19: 285–292.
- Vatrinet R., Leone G., De Luise M., Girolimetti G., Vidone M., Gasparre G., Porcelli A.M.: The α-ketoglutarate dehydrogenase complex in cancer metabolic plasticity. Cancer Metab., 2017; 5: 3.
- Jiang L., Shestov A.A., Swain P., Yang C., Parker S.J., Wang Q.A., Terada L.S., Adams N.D., McCabe M.T., Pietrak B., et al.: Reductive carboxylation supports redox homeostasis during anchorage-independent growth. Nature, 2016; 532: 255–258.
- Waters A., Zhdanov A., Papkovsky D.: Regulation of pyruvate dehydrogenase phosphorylation by hypoxia. FASEB J., 2014; 28: 572.4.
- Lin C.S., Liu L.T., Ou L.H., Pan S.C., Lin C.I., Wei Y.H.: Role of mitochondrial function in the invasiveness of human colon cancer cells. Oncol. Rep., 2018; 39: 316–330.
- Fiermonte G., Palmieri L., Todisco S., Agrimi G., Palmieri F., Walker J.E.: Identification of the mitochondrial glutamate transporter. Bacterial expression, reconstitution, functional characterization, and tissue distribution of two human isoforms. J. Biol. Chem., 2002; 277: 19289–19294.
- Molinari F., Raas-Rothschild A., Rio M., Fiermonte G., Encha-Razavi F., Palmieri L., Palmieri F., Ben-Neriah Z., Kadhom N., Vekemans M., et al.: Impaired mitochondrial glutamate transport in autosomal recessive neonatal myoclonic epilepsy. Am. J. Hum. Genet., 2005; 76: 334–339.
- Palmieri F.: The mitochondrial transporter family SLC25: Identification, properties and physiopathology. Mol. Aspects Med., 2013; 34: 465–484.
- Slater C., De La Mare J.A., Edkins A.L.: In vitro analysis of putative cancer stem cell populations and chemosensitivity in the SW480 and SW620 colon cancer metastasis model. Oncol. Lett., 2018; 15: 8516–8526.